ANALYST RECOMMENDATIONS : Abbott Laboratories, Intel, JPMorgan, PepsiCo, Roblox...
Every day, find a selection of analysts' recommendations covering North America and the UK. The list only includes companies that have been the subject of a change of opinion or price target, or of a new coverage. It may be updated during the session. This information is used to shed light on the movements of certain stocks or the market sentiment on a company.
- Abbott Laboratories: Barclays starts at overweight with $118 price target.
- Antofagasta: Morgan Stanley upgrades from Underweight to Overweight, targeting GBp 1220.
- Cleveland-Cliffs: Exane BNP Paribas downgrades to underperform from neutral. PT down 4% to $14.30.
- Dechra Pharmaceuticals: Jefferies upgrades from hold to buy targeting GBp 3112.
- Global Payments: Exane BNP Paribas downgrades to neutral from outperform. PT up 1.9% to $115.
- Intel: KGI Securities downgrades to underperform from neutral. PT down 32% to $18.
- Intuitive Surgical: Barclays starts at overweight with $235 price target.
- JPMorgan: Goldman Sachs adjusts price target to $136 from $130, maintains buy rating
- Juniper: Piper Sandler upgrades to neutral from underweight. PT up 9% to $29.
- Kimberly-Clark: Evercore ISI initiates coverage with in-line rating.
- NXP Semi: KGI Securities downgrades to neutral from outperform. PT up 9.7% to $155.
- PepsiCo: President Capital Management upgrades to buy from neutral. PT up 16% to $200.
- Potlatch: RBC Capital Markets upgrades to outperform from sector perform. PT up 29% to $55.
- Regeneron Pharmaceuticals: Evercore ISI downgrades to in line from outperform, keeps $760 price target.
- Roblox: Wedbush raises price target to $36 from $34, maintains neutral rating.
- RPM International: UBS cut its recommendation to neutral from buy. PT up 10% to $101.
- The Estee Lauder Co: Stifel Nicolaus adjusts price target to $275 from $315, maintains buy rating.
By 
